← 뒤로

The Initial Exploration of Polidocanol Sclerotherapy for the Treatment of Axillary Osmidrosis: A Retrospective Study.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2025 Vol.51(3) p. 290-295 🌐 cited 1 🔓 OA Sympathectomy and Hyperhidrosis Trea
OpenAlex 토픽 · Sympathectomy and Hyperhidrosis Treatments Dermatologic Treatments and Research Dupuytren's Contracture and Treatments

Yao S, Cai Y, Zhu C

관련 도메인

Abstract

[BACKGROUND] Axillary osmidrosis (AO) is a strong, unpleasant odor that originates from the apocrine axillary glands. Treatments of AO include surgical treatment and nonsurgical treatment. The surgical procedure yields effective results with a low recurrence rate but requires a longer recovery time and has more postoperative complications. Nonsurgical treatments are minimally invasive and safe, but short-term recurrence may occur in some cases.

[OBJECTIVE] Polidocanol sclerotherapy was first described for management of AO. This retrospective study explored the clinical efficacy in relieving symptom of AO assessed by AO severity using the axillary osmidrosis grading system and safety of polidocanol sclerotherapy in treating AO.

[PATIENTS AND METHODS] This retrospective study included 25 patients with AO single-site study, with 12 patients receiving polidocanol (1%) sclerotherapy (the polidocanol group) and 13 receiving botulinum toxin A (BTX-A) injection (the BTX-A group). The short-term efficacy (7 days after injection), the long-term efficacy (6 months after injection), the recurrence rate, and complications were compared between the 2 groups. A p-value of <0.05 was considered statistically significant.

[RESULTS] The short-term efficacies of polidocanol sclerotherapy and BTX-A injection were 100% and 69.2%, which was not clinically significant (p > .05), whereas their long-term efficacies were 100% and 46.2%, respectively (p < .05). The recurrence rates in the polidocanol and BTX-A groups were 25.0% and 84.6%, respectively (p < .05). The complications did not differ significantly between the 2 groups (p > .05). Although the short-term efficacy and complications were comparable between the 2 groups, the long-term efficacy of polidocanol sclerotherapy was superior to BTX-A injection. The polidocanol group has a lower recurrence rate than the BTX-A group.

[CONCLUSION] Polidocanol sclerotherapy may provide an effective and safe treatment with longer efficacy compared to toxin, which is an effective and safe option for AO treatment.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
약물 [BACKGROUND] Axillary scispacy 1
약물 [OBJECTIVE] Polidocanol scispacy 1
약물 BTX-A → botulinum toxin A scispacy 1
약물 polidocanol scispacy 1
질환 Axillary osmidrosis scispacy 1
질환 osmidrosis C0263472
Bromhidrosis
scispacy 1
기타 Axillary scispacy 1
기타 apocrine axillary glands scispacy 1
기타 botulinum toxin A scispacy 1

MeSH Terms

Humans; Polidocanol; Sclerotherapy; Retrospective Studies; Sclerosing Solutions; Female; Male; Axilla; Polyethylene Glycols; Adult; Middle Aged; Treatment Outcome; Sweat Gland Diseases; Botulinum Toxins, Type A; Recurrence; Odorants; Apocrine Glands; Young Adult; Aged

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문